Log In
Print this Print this

Valortim (formerly MDX-1303)

  Manage Alerts
Collapse Summary General Information
Company Bristol-Myers Squibb Co.
DescriptionHuman mAb, IgG1 (kappa) isotype targeting anthrax protective antigen (PA)
Molecular Target Bacillus anthracis protective antigen
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I
Standard IndicationAnthrax
Indication DetailsTreat and prevent anthrax infection; Treat anthrax infection
Regulatory Designation U.S. - Fast Track (Treat anthrax infection);
U.S. - Orphan Drug (Treat anthrax infection)
Partner PharmAthene Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today